Aug 4, 2026 08:00AM
Jun 22, 2026 07:30AM
Jun 22, 2026 07:30AM
Feb 25, 2025 08:00AM
Nov 14, 2024 07:01AM
Nov 14, 2024 07:00AM
Nov 5, 2024 07:00AM Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Oct 28, 2024 08:21AM
Oct 23, 2024 08:00AM
Oct 7, 2024 08:00AM
Sep 5, 2024 08:00AM
Aug 29, 2024 08:01AM
Aug 29, 2024 08:00AM
Aug 6, 2024 08:28AM Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
May 16, 2024 08:30AM
May 7, 2024 08:00AM
Apr 8, 2024 08:51AM
Apr 8, 2024 08:30AM
Apr 8, 2024 08:30AM
Mar 19, 2024 08:00AM
Mar 14, 2024 09:00AM Nuvectis Pharma (NVCT) Reports Encouraging Prelim Data from the NXP800 Phase 1b Trial
Mar 14, 2024 09:00AM
Mar 5, 2024 08:00AM
Feb 9, 2024 08:32AM
Feb 9, 2024 08:00AM
Jan 3, 2024 08:00AM
Dec 18, 2023 08:00AM
Nov 8, 2023 08:00AM Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
Oct 24, 2023 08:00AM
Sep 25, 2023 07:30PM
Sep 21, 2023 08:00AM
Sep 12, 2023 08:01AM
Sep 12, 2023 08:00AM
Sep 6, 2023 08:00AM
Sep 1, 2023 08:00AM Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Aug 17, 2023 08:00AM
Aug 9, 2023 08:00AM
Jun 20, 2023 08:02AM
Jun 20, 2023 08:00AM
May 15, 2023 08:03AM
May 15, 2023 08:00AM
May 10, 2023 08:00AM Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
Apr 27, 2023 10:14AM
Apr 27, 2023 08:00AM
Apr 18, 2023 08:00AM
Apr 18, 2023 08:00AM
Apr 10, 2023 08:01AM
Apr 10, 2023 08:00AM
Apr 10, 2023 08:00AM Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Mar 7, 2023 08:00AM

330,004 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All